Business Context and Reporting Period
This Form 8-K Current Report, dated November 16, 2023, details a material definitive agreement entered into by Dermata Therapeutics, Inc. (DRMA), a Delaware corporation and emerging growth company. The filing reports on an inducement offer letter agreement executed on November 16, 2023, with a holder of existing warrants to purchase the Company's common stock.
Key Financial Metrics and Transaction Details
- Transaction Type: Inducement to exercise existing warrants in exchange for new warrants.
- Existing Warrants Exercised: 3,472,095 shares at a reduced exercise price of $0.6511 per share (original price was $2.82).
- Expected Gross Proceeds: Approximately $2.26 million from the exercise of existing warrants.
- New Warrants Issued:
- Series A: 3,707,944 shares exercisable for 5 years.
- Series B: 3,236,246 shares exercisable for 28 months.
- Exercise Price: $0.6511 per share for both series.
- Placement Agent Fees:
- Cash fee: 7.0% of gross proceeds.
- Management fee: 1.0% of gross proceeds.
- Reimbursable expenses: $25,000 (non-accountable) + $15,950 (clearing costs).
- Placement Agent Warrants: 243,047 shares at an exercise price of $0.8139.
- Use of Proceeds: General corporate purposes, including research, pre-clinical studies, clinical trials, technology development, licensing, and working capital.
Material Changes and Conditions
The primary material change is the reduction of the exercise price for existing warrants from $2.82 to $0.6511 per share to induce cash exercise. This transaction is subject to customary closing conditions, with a closing expected on or about November 20, 2023. The Company has agreed to a 45-day lock-up period on issuing new common stock or equivalents and a one-year restriction on Variable Rate Transactions following the closing date.
Outlook, Risks, and Contingencies
- Stockholder Approval: Exercise of the New Warrants is contingent upon stockholder approval pursuant to Nasdaq Listing Rule 5635(d). The Company must convene a meeting within 90 days of the closing date.
- Registration Rights: The Company must file a Form S-3 resale registration statement for the New Warrant Shares and use commercially reasonable efforts to have it declared effective within 90 days of the inducement letter date.
- Ownership Caps: Holders are restricted from exercising warrants if it would result in ownership exceeding 4.99% (or up to 9.99% with notice) of outstanding common stock.
- Fundamental Transactions: In the event of a merger or acquisition, holders may receive shares of the successor entity or cash equal to the Black Scholes Value of the unexercised warrants.
Investor Verification Checklist
- Verify the actual closing date and confirmation of the $2.26 million gross proceeds receipt.
- Monitor the scheduling and outcome of the stockholder meeting required for New Warrant approval.
- Confirm the effectiveness of the Form S-3 resale registration statement for the New Warrant Shares.
- Review the Company's cash position post-closing to assess runway for clinical trials and operations.
- Check for any subsequent filings regarding the 45-day lock-up period expiration or new equity issuances.